Literature DB >> 34981477

The Role of Chemokines in Cardiovascular Diseases and the Therapeutic Effect of Curcumin on CXCL8 and CCL2 as Pathological Chemokines in Atherosclerosis.

Mahdiyeh Hedayati-Moghadam1, Sara Hosseinian2, Maryam Paseban3, Arezoo Gowhari Shabgah4, Jamshid Gholizadeh4, Tannaz Jamialahmadi5,6, Thozhukat Sathyapalan7, Amirhossein Sahebkar8,9,10.   

Abstract

Curcumin, as a vegetative flavonoid, has a protective and therapeutic role in various adverse states such as oxidative stress and inflammation. Remedial properties of this component have been reported in the different chronic diseases including cancers (myeloma, pancreatic, breast, colorectal), vitiligo, psoriasis, neuropathic pains, inflammatory disorders (osteoarthritis, uveitis, ulcerative colitis, Alzheimer), cardiovascular conditions, and diabetes.Cardiovascular disorders include atherosclerosis and various manifestations of atherosclerosis such as stroke, and myocardial infarction (MI) is the leading cause of mortality globally. Studies have shown varying expressions of inflammatory and non-inflammatory chemokines and chemokine receptors in cardiovascular disease, which have been highlighted first in this review. The alteration in chemokines secretion and chemokine receptors has an essential role in the pathophysiology of cardiovascular disease. Chemokines as cytokines with low molecular weight (8-12 kDa) mediate white blood cell (WBC) chemotactic reactions, vascular cell migration, and proliferation that induce endothelial dysfunction, atherogenesis, and cardiac hypertrophy.Several studies reported that curcumin could be advantageous in the attenuation of cardiovascular diseases via anti-inflammatory effects and redress of chemokine secretion and chemokine receptors. We present these studies with a focus on two chemokines: CXCL8 (IL-8) and CCL2 (chemoattractant protein 1 or MCP-1). Future research will further elucidate the precise potential of curcumin on chemokines in the adjustment of cardiovascular system activity or curcumin chemokine-based therapies.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Angiotensin; CCL2; CXCL8; Cardiovascular disorders; Curcumin

Mesh:

Substances:

Year:  2021        PMID: 34981477     DOI: 10.1007/978-3-030-73234-9_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  112 in total

Review 1.  Cellular immunity and cardiac remodeling after myocardial infarction: role of neutrophils, monocytes, and macrophages.

Authors:  Hisahito Shinagawa; Stefan Frantz
Journal:  Curr Heart Fail Rep       Date:  2015-06

2.  IL-17 stimulates the expression of CCL2 in cardiac myocytes via Act1/TRAF6/p38MAPK-dependent AP-1 activation.

Authors:  Shiyou Du; Zhuolun Li; Xin Xie; Congfeng Xu; Xinhe Shen; Nan Wang; Yan Shen
Journal:  Scand J Immunol       Date:  2019-10-20       Impact factor: 3.487

Review 3.  Inflammation and repair in the ischaemic myocardium.

Authors:  F K Swirski
Journal:  Hamostaseologie       Date:  2014-11-06       Impact factor: 1.778

4.  Effect of plasma C-reactive protein levels in modulating the risk of coronary heart disease associated with small, dense, low-density lipoproteins in men (The Quebec Cardiovascular Study).

Authors:  Annie C St-Pierre; Jean Bergeron; Matteo Pirro; Bernard Cantin; Gilles R Dagenais; Jean-Pierre Després; Benoît Lamarche
Journal:  Am J Cardiol       Date:  2003-03-01       Impact factor: 2.778

Review 5.  Role of inflammation in the progression of heart failure.

Authors:  Arne Yndestad; Jan Kristian Damås; Erik Øie; Thor Ueland; Lars Gullestad; Pål Aukrust
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

Review 6.  The inflammatory response in myocardial injury, repair, and remodelling.

Authors:  Nikolaos G Frangogiannis
Journal:  Nat Rev Cardiol       Date:  2014-03-25       Impact factor: 32.419

Review 7.  Cardiovascular disease risk factors: epidemiology and risk assessment.

Authors:  Björn Dahlöf
Journal:  Am J Cardiol       Date:  2010-01-04       Impact factor: 2.778

8.  Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis.

Authors:  Florian Leuschner; Philipp J Rauch; Takuya Ueno; Rostic Gorbatov; Brett Marinelli; Won Woo Lee; Partha Dutta; Ying Wei; Clinton Robbins; Yoshiko Iwamoto; Brena Sena; Aleksey Chudnovskiy; Peter Panizzi; Edmund Keliher; John M Higgins; Peter Libby; Michael A Moskowitz; Mikael J Pittet; Filip K Swirski; Ralph Weissleder; Matthias Nahrendorf
Journal:  J Exp Med       Date:  2012-01-02       Impact factor: 14.307

Review 9.  Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?

Authors:  Paul Welsh; Gianluca Grassia; Shani Botha; Naveed Sattar; Pasquale Maffia
Journal:  Br J Pharmacol       Date:  2017-06-10       Impact factor: 8.739

Review 10.  Anti-inflammatory Action of Curcumin and Its Use in the Treatment of Lifestyle-related Diseases.

Authors:  Kana Shimizu; Masafumi Funamoto; Yoichi Sunagawa; Satoshi Shimizu; Yasufumi Katanasaka; Yusuke Miyazaki; Hiromichi Wada; Koji Hasegawa; Tatsuya Morimoto
Journal:  Eur Cardiol       Date:  2019-07-11
View more
  4 in total

Review 1.  Role of chemokine systems in cancer and inflammatory diseases.

Authors:  Hongyi Li; Min Wu; Xia Zhao
Journal:  MedComm (2020)       Date:  2022-06-08

2.  Rosmarinic Acid Attenuates the Lipopolysaccharide-Provoked Inflammatory Response of Vascular Smooth Muscle Cell via Inhibition of MAPK/NF-κB Cascade.

Authors:  Ching-Pei Chen; You-Cian Lin; Yu-Hui Peng; Han-Min Chen; Jiun-Tsai Lin; Shao-Hsuan Kao
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-31

Review 3.  Noradrenaline in Alzheimer's Disease: A New Potential Therapeutic Target.

Authors:  Irene L Gutiérrez; Cinzia Dello Russo; Fabiana Novellino; Javier R Caso; Borja García-Bueno; Juan C Leza; José L M Madrigal
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

4.  Deciphering the combination mechanisms of Gualou-Xiebai herb pair against atherosclerosis by network pharmacology and HPLC-Q-TOF-MS technology.

Authors:  Yarong Liu; Hua Zhong; Pengbo Xu; An Zhou; Lidan Ding; Jingwen Qiu; Hongfei Wu; Min Dai
Journal:  Front Pharmacol       Date:  2022-09-01       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.